Important variables to know: partnership compan
Post# of 149149
partnership company name
Stand alone treatment or combo? Human trial(s) funded to the tune of how much? Are we doing the trials or are they?
How many shares will be in our float when this happens?
Will this result in an uplisting and/or analyst coverage?
How large is the market for MASH and what % would we treat? How much revenue and what would be the split if any, vs set payments.
What is the average dollar cost average of the thousands of shareholders at that point and are they greedy long term or short term? How many just want to break even?
Anything could happen with "news" but I'd guess a pop that gets overbought initially, settles back and as the clinical progress shows efficacy and an FDA approval $5-6 bucks anyway.
What is the current P/E for average biotechs in this situation? I have no clue and I don't know how a partnership affects the potential PPS.